trending Market Intelligence /marketintelligence/en/news-insights/trending/X_e6EuRnnsyrk8V9cC7bfQ2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

VistaGen's nasal spray wins US FDA fast-track designation for anxiety disorder

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

VistaGen's nasal spray wins US FDA fast-track designation for anxiety disorder

The U.S. Food and Drug Administration granted the fast-track designation to VistaGen Therapeutics Inc.'s nasal spray PH94B.

SNL Image

The company was evaluating PH94B as a treatment that is nonaddictive, nonsedating and can be taken as and when needed, VistaGen said, adding that the company is preparing for PH94B's phase 3 trials. The South San Francisco, Calif.-based biopharmaceutical company's treatment is aimed at treating social anxiety disorder.

Fast-track designation gives regulatory priority to treatments that show promise, including frequent meetings with the FDA and priority review of the marketing application.

VistaGen also has a depression medicine, called AV-101, which has failed two mid-stage studies.